Literature DB >> 32109714

A literature review of treatment-specific clinical prediction models in patients with breast cancer.

Natansh D Modi1, Michael J Sorich2, Andrew Rowland2, Jessica M Logan3, Ross A McKinnon2, Ganessan Kichenadasse2, Michael D Wiese3, Ashley M Hopkins2.   

Abstract

Despite advances in the breast cancer treatment, significant variability in patient outcomes remain. This results in significant stress to patients and clinicians. Treatment-specific clinical prediction models allow patients to be matched against historical outcomes of patients with similar characteristics; thereby reducing uncertainty by providing personalised estimates of benefits, harms, and prognosis. To achieve this objective, models need to be clinical-grade with evidence of accuracy, reproducibility, generalizability, and be user-friendly. A structured search was undertaken to identify treatment-specific clinical prediction models for therapeutic or adverse outcomes in breast cancer using clinicopathological data. Significant gaps in the presence of validated models for available treatments was identified, along with gaps in prediction of therapeutic and adverse outcomes. Most models did not have user-friendly tools available. With the aim being to facilitate the selection of the best medicine for a specific patient and shared-decision making, future research will need to address these gaps.
Copyright © 2020 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Breast cancer; Clinical prediction model; Literature review; Treatment-specific

Year:  2020        PMID: 32109714     DOI: 10.1016/j.critrevonc.2020.102908

Source DB:  PubMed          Journal:  Crit Rev Oncol Hematol        ISSN: 1040-8428            Impact factor:   6.312


  5 in total

1.  Patient-Reported Outcomes Predict Progression-Free Survival of Patients with Advanced Breast Cancer Treated with Abemaciclib.

Authors:  Sarah Badaoui; Ganessan Kichenadasse; Andrew Rowland; Michael J Sorich; Ashley M Hopkins
Journal:  Oncologist       Date:  2021-05-11

2.  Machine Learning for Prediction of Survival Outcomes with Immune-Checkpoint Inhibitors in Urothelial Cancer.

Authors:  Ahmad Y Abuhelwa; Ganessan Kichenadasse; Ross A McKinnon; Andrew Rowland; Ashley M Hopkins; Michael J Sorich
Journal:  Cancers (Basel)       Date:  2021-04-21       Impact factor: 6.639

3.  Molecular investigation of possible relationships concerning bovine leukemia virus and breast cancer.

Authors:  Zanib Khan; Muhammad Abubakar; Muhammad Javed Arshed; Roohi Aslam; Sadia Sattar; Naseer Ali Shah; Sundus Javed; Aamira Tariq; Nazish Bostan; Shumaila Manzoor
Journal:  Sci Rep       Date:  2022-03-09       Impact factor: 4.379

4.  Impact of Adjuvant Treatment on Heparanase Concentration in Invasive, Unilateral Breast Cancer Patients: Results of a Prospective Single-Centre Cohort Study.

Authors:  Barbara Ruszkowska-Ciastek; Kornel Bielawski; Elżbieta Zarychta; Piotr Rhone
Journal:  J Clin Med       Date:  2021-05-18       Impact factor: 4.241

5.  Value of the Lung Immune Prognostic Index in Patients with Non-Small Cell Lung Cancer Initiating First-Line Atezolizumab Combination Therapy: Subgroup Analysis of the IMPOWER150 Trial.

Authors:  Ashley M Hopkins; Ganessan Kichenadasse; Ahmad Y Abuhelwa; Ross A McKinnon; Andrew Rowland; Michael J Sorich
Journal:  Cancers (Basel)       Date:  2021-03-09       Impact factor: 6.639

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.